AstraZeneca PLC (AZN)vsDelcath Systems Inc (DCTH)
AZN
AstraZeneca PLC
$171.61
-3.85%
HEALTHCARE · Cap: $302.65B
DCTH
Delcath Systems Inc
$13.01
-3.77%
HEALTHCARE · Cap: $446.71M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 66727% more annual revenue ($60.44B vs $90.44M). AZN leads profitability with a 17.2% profit margin vs 0.6%. AZN appears more attractively valued with a PEG of 1.46. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
DCTH
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+2.2%
Fair Value
$194.36
Current Price
$171.61
$22.75 discount
Intrinsic value data unavailable for DCTH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Revenue surging 26.3% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.5% — below average capital efficiency
0.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 26.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, Market Cap, Return on Equity. A P/E of 1294.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while DCTH is a growth play — different risk/reward profiles.
DCTH carries more volatility with a beta of 0.52 — expect wider price swings.
DCTH is growing revenue faster at 26.3% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 35/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?